Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients undergoing neoadjuvant chemotherapy: A systematic review and meta-analysis

Table 2 Subgroup analysis of overall survival in patients with neoadjuvant chemotherapy for gastric cancer

Subgroup	OS
	Study	HR (95%CI)	P value	I2
Total	10	1.76 (1.22-2.54)	0.003	58%
Time of test
Pre-NAC	10	1.76 (1.22-2.54)	0.003	58%
Post-NAC	8	1.83 (1.22-2.75)	0.004	59%
Age
≥ 60 years	6	2.13 (1.24-3.67)	0.006	70%
< 60 years	4	1.40 (0.79-2.48)	0.25	37%
Region
Asia	6	1.36 (0.94-1.97)	0.1	37%
Africa	1	3.26 (1.14-9.28)	0.03	NA
Europe	3	2.36 (1.02-5.44)	0.04	65%
NLR cut-off
≥ 2	5	1.99 (1.01-3.94)	0.049	73%
< 2	5	1.65 (1.11-2.46)	0.01	12%

NAC: Neoadjuvant chemotherapy; NLR: Neutrophil to lymphocyte ratio; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval.